Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes

Pharmacogenomics

Volumn 13, Issue 8, 2012, Pages 847-849

  Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

HCV RNA; hepatitis C virus; IL28B; IP 10; liver histology

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ALLELE; ANTIVIRAL THERAPY; ASIAN; CAUCASIAN; EDITORIAL; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER HISTOLOGY; LIVER TRANSPLANTATION; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

BIOMARKERS, PHARMACOLOGICAL; GENETIC ASSOCIATION STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84862025131     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.57     Document Type: Editorial

References (20)

1. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
2. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401(2009).
3. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
4. Bochud PY, Bibert S, Negro F et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J. Hepatol. 55(5), 980-988 (2011).
5. Lagging M, Askarieh G, Negro F et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 6(2), e17232 (2011).
6. Sarrazin C, Susser S, Doehring A et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 54(3), 415-421 (2011).
7. Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139(3), 821-827, 827.e1 (2010).
8. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
9. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139(2), 499-509 (2010).
10. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140(3), 1021-1031 (2011).
11. Abe H, Ochi H, Maekawa T et al. Common variation of IL28 affects γ-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 53(3), 439-443 (2010).
12. Tillmann HL, Patel K, Muir AJ et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J. Hepatol. 55(6), 1195-1200 (2011).
13. Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, Lagging M. Association between IL28B-related genetic variants and liver histopathology differs between hcv genotypes. Hepatology doi:10.1002/hep.25598 (2012) (Epub ahead of print).
14. Rembeck K, Alsio A, Christensen PB et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 7(1), e29370 (2012).
15. Bochud PY, Bibert S, Kutalik Z et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55(2), 384-394 (2012).
16. Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53(1), 317-324 (2011).
17. Jacobson IM, Catlett I, Marcellin P et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the Advance trial. J. Hepatol. 54(Suppl. 1), S542 (2011).
18. Poordad F, Bronowicki JP, Gordon SC et al. IL28B polymorphism predicts viologic response in patients with hepatitis C genotype 1 treated with Boceprevir (BOC) combination therapy. J. Hepatol. 54(Suppl. 1), S6 (2011).
19. Lagging M, Romero AI, Westin J et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44(6), 1617-1625 (2006).
20. Darling JM, Aerssens J, Fanning G et al. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53(1), 14-22 (2011).